Remedix Surgibay Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-12-2024
- Paid Up Capital ₹ 0.20 M
as on 26-12-2024
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit -23.02%
(FY 2020)
- Ebitda 164.92%
(FY 2020)
- Net Worth -14.31%
(FY 2020)
- Total Assets -4.45%
(FY 2020)
About Remedix Surgibay
The Company is engaged in the Non-Profit Organizations Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vishal Rauniyar and Shraddha Srivastava serve as directors at the Company.
- CIN/LLPIN
U85320UP2017PTC097852
- Company No.
097852
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Oct 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Remedix Surgibay Private Limited offer?
Remedix Surgibay Private Limited offers a wide range of products and services, including Hand Sanitizer & Disinfectant, Hand Sanitizer Spray, Blood Pressure Machine, Dr Morepen Blood Pressure Machine, Pulse Oximeter, Glucometer & POCT Devices, Pulse Oximeter, Face Mask, Disposable Face Mask, 3 Ply Face Mask, Sutures.
Who are the key members and board of directors at Remedix Surgibay?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishal Rauniyar  | Director | 13-Oct-2017 | Current |
| Shraddha Srivastava | Director | 05-Apr-2021 | Current |
Financial Performance of Remedix Surgibay.
Remedix Surgibay Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 23.02% decrease in profit. The company's net worth observed a substantial decline by a decrease of 14.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Remedix Surgibay?
Unlock access to Remedix Surgibay's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Remedix Surgibay?
Unlock and access historical data on people associated with Remedix Surgibay, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Remedix Surgibay, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Remedix Surgibay's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
